Effect of α1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X

Stuart D. Rosen, Roberto Lorenzoni, Juan Carlos Kaski, Rodney A. Foale, Paolo G. Camici

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We sought to test the response of the coronary microcirculation to α- adrenoceptor blockade in patients with syndrome X (angina, ischemia-like stress electrocardiogram, and a normal coronary arteriogram). The response of the microcirculation was assessed by quantification of coronary vasodilator reserve (the ratio of hyperemic to resting myocardial blood flow). We investigated 28 patients with syndrome X [18 women, age 54.4 (7.6) years]. Myocardial blood flow was measured at rest and after dipyridamole by using positron emission tomography with H2 15O. The measurements were made before and after treatment for 10 days with doxazosin (1 mg o.d. for 3 days, followed by 2 mg o.d. for 7 days) or a matched placebo, similarly administered. Patients were randomized to α1-blockade or to placebo in double-blind fashion. No significant differences were demonstrable between syndrome X patients treated with doxazosin and those receiving placebo, with respect to resting myocardial blood flow, myocardial blood flow after dipyridamole, or coronary vasodilator reserve (the ratio of the latter two). In addition, no relations were demonstrable among myocardial blood flow, coronary vasodilator reserve, development of chest pain after dipyridamole, or development of ischemia-like ECG changes. Doxazosin had no effect on the perception of chest pain after dipyridamole. No differences were found between the effects of α1-blockade with doxazosin or those of placebo with respect to myocardial blood flow in syndrome X. The values obtained for myocardial blood flow and coronary vasodilator reserve for the patients were within the normal range. The data do not support the case for α1-mediated vasoconstriction having an etiologic role in the chest pain of syndrome X.

Original languageEnglish
Pages (from-to)554-560
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume34
Issue number4
DOIs
Publication statusPublished - Oct 1999

Fingerprint

Microvascular Angina
Vasodilator Agents
Adrenergic Receptors
Doxazosin
Dipyridamole
Chest Pain
Placebos
Microcirculation
Electrocardiography
Ischemia
Vasoconstriction
Positron-Emission Tomography
Reference Values

Keywords

  • α Adrenoceptor
  • Chest pain
  • Myocardial blood flow
  • Positron emission tomography
  • Syndrome X

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Effect of α1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X. / Rosen, Stuart D.; Lorenzoni, Roberto; Kaski, Juan Carlos; Foale, Rodney A.; Camici, Paolo G.

In: Journal of Cardiovascular Pharmacology, Vol. 34, No. 4, 10.1999, p. 554-560.

Research output: Contribution to journalArticle

Rosen, Stuart D. ; Lorenzoni, Roberto ; Kaski, Juan Carlos ; Foale, Rodney A. ; Camici, Paolo G. / Effect of α1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X. In: Journal of Cardiovascular Pharmacology. 1999 ; Vol. 34, No. 4. pp. 554-560.
@article{9e8991bdd0704abda79044bba24e861c,
title = "Effect of α1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X",
abstract = "We sought to test the response of the coronary microcirculation to α- adrenoceptor blockade in patients with syndrome X (angina, ischemia-like stress electrocardiogram, and a normal coronary arteriogram). The response of the microcirculation was assessed by quantification of coronary vasodilator reserve (the ratio of hyperemic to resting myocardial blood flow). We investigated 28 patients with syndrome X [18 women, age 54.4 (7.6) years]. Myocardial blood flow was measured at rest and after dipyridamole by using positron emission tomography with H2 15O. The measurements were made before and after treatment for 10 days with doxazosin (1 mg o.d. for 3 days, followed by 2 mg o.d. for 7 days) or a matched placebo, similarly administered. Patients were randomized to α1-blockade or to placebo in double-blind fashion. No significant differences were demonstrable between syndrome X patients treated with doxazosin and those receiving placebo, with respect to resting myocardial blood flow, myocardial blood flow after dipyridamole, or coronary vasodilator reserve (the ratio of the latter two). In addition, no relations were demonstrable among myocardial blood flow, coronary vasodilator reserve, development of chest pain after dipyridamole, or development of ischemia-like ECG changes. Doxazosin had no effect on the perception of chest pain after dipyridamole. No differences were found between the effects of α1-blockade with doxazosin or those of placebo with respect to myocardial blood flow in syndrome X. The values obtained for myocardial blood flow and coronary vasodilator reserve for the patients were within the normal range. The data do not support the case for α1-mediated vasoconstriction having an etiologic role in the chest pain of syndrome X.",
keywords = "α Adrenoceptor, Chest pain, Myocardial blood flow, Positron emission tomography, Syndrome X",
author = "Rosen, {Stuart D.} and Roberto Lorenzoni and Kaski, {Juan Carlos} and Foale, {Rodney A.} and Camici, {Paolo G.}",
year = "1999",
month = "10",
doi = "10.1097/00005344-199910000-00012",
language = "English",
volume = "34",
pages = "554--560",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effect of α1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X

AU - Rosen, Stuart D.

AU - Lorenzoni, Roberto

AU - Kaski, Juan Carlos

AU - Foale, Rodney A.

AU - Camici, Paolo G.

PY - 1999/10

Y1 - 1999/10

N2 - We sought to test the response of the coronary microcirculation to α- adrenoceptor blockade in patients with syndrome X (angina, ischemia-like stress electrocardiogram, and a normal coronary arteriogram). The response of the microcirculation was assessed by quantification of coronary vasodilator reserve (the ratio of hyperemic to resting myocardial blood flow). We investigated 28 patients with syndrome X [18 women, age 54.4 (7.6) years]. Myocardial blood flow was measured at rest and after dipyridamole by using positron emission tomography with H2 15O. The measurements were made before and after treatment for 10 days with doxazosin (1 mg o.d. for 3 days, followed by 2 mg o.d. for 7 days) or a matched placebo, similarly administered. Patients were randomized to α1-blockade or to placebo in double-blind fashion. No significant differences were demonstrable between syndrome X patients treated with doxazosin and those receiving placebo, with respect to resting myocardial blood flow, myocardial blood flow after dipyridamole, or coronary vasodilator reserve (the ratio of the latter two). In addition, no relations were demonstrable among myocardial blood flow, coronary vasodilator reserve, development of chest pain after dipyridamole, or development of ischemia-like ECG changes. Doxazosin had no effect on the perception of chest pain after dipyridamole. No differences were found between the effects of α1-blockade with doxazosin or those of placebo with respect to myocardial blood flow in syndrome X. The values obtained for myocardial blood flow and coronary vasodilator reserve for the patients were within the normal range. The data do not support the case for α1-mediated vasoconstriction having an etiologic role in the chest pain of syndrome X.

AB - We sought to test the response of the coronary microcirculation to α- adrenoceptor blockade in patients with syndrome X (angina, ischemia-like stress electrocardiogram, and a normal coronary arteriogram). The response of the microcirculation was assessed by quantification of coronary vasodilator reserve (the ratio of hyperemic to resting myocardial blood flow). We investigated 28 patients with syndrome X [18 women, age 54.4 (7.6) years]. Myocardial blood flow was measured at rest and after dipyridamole by using positron emission tomography with H2 15O. The measurements were made before and after treatment for 10 days with doxazosin (1 mg o.d. for 3 days, followed by 2 mg o.d. for 7 days) or a matched placebo, similarly administered. Patients were randomized to α1-blockade or to placebo in double-blind fashion. No significant differences were demonstrable between syndrome X patients treated with doxazosin and those receiving placebo, with respect to resting myocardial blood flow, myocardial blood flow after dipyridamole, or coronary vasodilator reserve (the ratio of the latter two). In addition, no relations were demonstrable among myocardial blood flow, coronary vasodilator reserve, development of chest pain after dipyridamole, or development of ischemia-like ECG changes. Doxazosin had no effect on the perception of chest pain after dipyridamole. No differences were found between the effects of α1-blockade with doxazosin or those of placebo with respect to myocardial blood flow in syndrome X. The values obtained for myocardial blood flow and coronary vasodilator reserve for the patients were within the normal range. The data do not support the case for α1-mediated vasoconstriction having an etiologic role in the chest pain of syndrome X.

KW - α Adrenoceptor

KW - Chest pain

KW - Myocardial blood flow

KW - Positron emission tomography

KW - Syndrome X

UR - http://www.scopus.com/inward/record.url?scp=0032589376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032589376&partnerID=8YFLogxK

U2 - 10.1097/00005344-199910000-00012

DO - 10.1097/00005344-199910000-00012

M3 - Article

VL - 34

SP - 554

EP - 560

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -